Immuno-oncology firm Genelux's Q3 net loss beats expectations

Genelux

05/11/2025 22:49

Overview

Genelux Q3 net loss of $7.95 mln beats analyst expectations

Company has $21 mln in cash and investments, funding operations into Q3 2026

Outlook

Company expects cash resources to support operations into Q3 2026

Result Drivers

R&D EXPENSES - Increase in R&D expenses driven by stock compensation and clinical trial costs for Phase 3 OnPrime trial

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Beat
-$7.95 mln
-$8.14 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Genelux Corp is $18.00, about 54.9% above its November 4 closing price of $8.11

Press Release: ID:nGNX1J8BVP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)